A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer

This study has been completed.

Study NCT00509769 Information provided by Genentech

First Received: July 27, 2007 Last Updated: April 20, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Study Completion Date:	June 2009
Estimated Primary Completion Date:	No date given